Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S. Tam, Andrew W. Roberts, Sasanka M. Handunnetti et al.|New England Journal of Medicine|2018Cited by 429
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Sarah‐Jane Dawson, Yih-Chih Chan et al.|Nature Medicine|2018Cited by 204